Business
CAPR Stockholders with Large Losses Should Contact Robbins LLP Before the Lead Plaintiff Deadline for Information About Leading the Capricor Therapeutics, Inc. Class Action Lawsuit
CAPR Stockholders with Large Losses Should Contact Robbins LLP Before the Lead Plaintiff Deadline...
About this update from Caprock Mining Corp
[{"type":"text","content":"CAPR Stockholders with Large Losses Should Contact Robbins LLP Before the Lead Plaintiff Deadline for Information About Leading the Capricor Therapeutics, Inc. Class Action Lawsuit\n\n\n\n CAPR Stockholders with Large Losses Should Contact Robbins LLP Before the Lead Plaintiff Deadline for Information About Leading the Capricor Therapeutics, Inc. Class Action Lawsuit\n \n\n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n\n\n\n\n\n PR Newswire\n \n\n\n\n\n\n SAN DIEGO\n \n\n ,\n \n\n Aug. 26, 2025\n \n\n /PRNewswire/ --\n \n Robbins LLP\n \n reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Capricor Therapeutics, Inc. (NASDAQ: CAPR) securities between\n \n October 9, 2024\n \n and\n \n July 10, 2025\n \n .  Capricor is a clinical-stage biotechnology company that engages in the development of transformative cell and exosome-based therapeutics for treating\n \n\n\n\n\n\n\n\n\n Duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in\n \n the United States\n \n . Its lead product candidate is deramiocel, an allogeneic cardiosphere-derived cells.\n \n\n For more information, submit a\n \n form\n \n ,\n \n email\n \n attorney\n \n Aaron Dumas, Jr.\n \n , or give us a call at (800) 350-6003.\n \n\n\n The Allegations:\n \n Robbins LLP is Investigating Allegations that Capricorn Therapeutics, Inc. (CAPR) Misled Investors Regarding the Viability of Deramiocel\n \n\n According to the complaint, during the class period, defendants misled investors concerning Capricor's lead cell therapy candidate drug deramiocel for the treatment of cardiomyopathy associated with DMD. Defendants gave the false impression that they could obtain first approval for DMD cardiomyopathy, while, at the same time, concealing material adverse facts concerning its four-year safety and efficacy data from its Phase 2 HOPE-2 trial study of deramiocel. This caused Plaintiff and other shareholders to purchase Capricor's securities at artificially inflated prices.\n \n\n Plaintiff\n \n alleges\n \n that on\n \n July 11, 2025\n \n , C...